How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion. And developers of AI are becoming attractive acquisition targets for contract research organizations, according to Ulrik Kristensen, PhD, research analyst and founder of Emersion Insights. Read More
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event. Read More
Tackling the next hurdle in cell and gene therapy: Manufacturing
Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies is still playing catch-up. A group of investors and executives from across the industry discussed this issue in an on-demand session of the Biotech Showcase virtual event. Read More
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15. Read More
Are biotech companies really high-risk investments?
Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that over the long term, biotech firms that went public performed just as well as nonbiotech companies by various measures of financial success. Read More
Top Operation Warp Speed official shares lessons learned from COVID-19
The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That's according to Moncef Slaoui, PhD, chief adviser of the U.S. government's Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5. Read More
COVID-19 to have long-lasting effect on biotech industry
The COVID-19 pandemic will have a widespread and long-lasting effect on the biotechnology industry, according to speakers at a January 5 presentation held in advance of the Biotech Showcase virtual event taking place January 11-15. Biotech companies have pivoted on a massive scale to pursue infectious disease research -- and not all of them will be successful. Read More
Allergic reactions to COVID-19 vaccines shouldn't stop vaccinations
COVID-19 vaccines currently approved for emergency use by the U.S. Food and Drug Administration are safe even among people with food or medication allergies, according to allergists from Massachusetts General Hospital. A review of all relevant information was published in the Journal of Allergy and Clinical Immunology: In Practice on December 31. Read More
Top 10 ScienceBoard stories for 2020
For many of us, 2020 did not pan out as planned. The emergence of the COVID-19 pandemic has drastically changed our daily lives. Here at ScienceBoard.net, we have provided timely and evidence-based information to our readers regarding COVID-19, as well as many other topics in the biopharmaceutical and life sciences industries. Read More
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the messenger RNA (mRNA) COVID-19 vaccine from Moderna. The company's mRNA-1273 vaccine now becomes the second COVID-19 vaccine on the U.S. market, after a vaccine from Pfizer and BioNTech was granted an EUA last week. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter